Aquestive Therapeutics Inc
NASDAQ:AQST
Aquestive Therapeutics Inc
EPS (Diluted)
Aquestive Therapeutics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
EPS (Diluted)
$0
|
CAGR 3-Years
35%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
EPS (Diluted)
$5
|
CAGR 3-Years
-9%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
EPS (Diluted)
-$4
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
EPS (Diluted)
$1
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
0%
|
|
|
Merck & Co Inc
NYSE:MRK
|
EPS (Diluted)
$6
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
EPS (Diluted)
$11
|
CAGR 3-Years
24%
|
CAGR 5-Years
6%
|
CAGR 10-Years
18%
|
|
Aquestive Therapeutics Inc
Glance View
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 157 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The company is engaged in advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. The firm's CNS portfolio, which is focused on epilepsy includes Sympazan and Libervant. The active programs in its complex molecule pipeline portfolio are: AQST-109-SF, AQST-108-SF, and AQST-108-SF. Its PharmFilm technology develops medicines that offer non-invasive delivery, customized suitability for patients with dysphagia, or trouble swallowing, can be administered without water and ensures consistent therapeutic dosing. PharmFilm is comprised of polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place.
See Also
What is Aquestive Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-0.5
USD
Based on the financial report for Dec 31, 2024, Aquestive Therapeutics Inc's EPS (Diluted) amounts to -0.5 USD.
What is Aquestive Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
28%
Over the last year, the EPS (Diluted) growth was -292%. The average annual EPS (Diluted) growth rates for Aquestive Therapeutics Inc have been 35% over the past three years , 28% over the past five years .
You don't have any saved screeners yet